Eigen Therapeutics

Eigen Therapeutics is a biotechnology company on a mission to make therapies that make cancer easier to find and eliminate. Eigen is focused on the development of “priming” therapies, therapies that help targeted therapies reach their full potential by addressing cancer heterogeneity, making cancer cells more vulnerable and/or making healthy cells more resilient to treatment.

Eigen is building a high-throughput discovery platform to explore the space of priming therapies, leveraging proprietary machine learning algorithms to discover novel associations, new classes of drugs, and new potential therapies that change a cell's state to make it more vulnerable to a targeted therapy. The Eigen platform represents the intersection of biology and engineering, and includes robotic systems, laboratory operations software, and machine learning analysis pipelines—all developed in-house—with the ultimate goal of saving more lives.

Eigen Therapeutics headquartered in United States, North America, operates in the Biotechnology, Life Science sector. The company focuses on Biotechnology and has secured $224.0M in funding across 32 round(s). With a team of 1-10 employees, Eigen Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Eigen Therapeutics, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.